October Term 2016 · Docket 15-1039

When must a biosimilar maker share data with the original drug sponsor?

Sandoz and Amgen dispute the timing of data exchange required before patent litigation can begin.

Official caption
Sandoz Inc. v. Amgen Inc.
Latest argument session
Latest official Court activity
Latest verified event
Argued
Sources analyzed through
Official Transcript

Verified source milestones

  1. — An official oral-argument transcript was verified.
  2. — An official oral-argument transcript was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Ms. Maynard argued the lower court issued a federal judgment.

    Ms. Maynard stated Congress provided for injunctive relief in the statute.

    Mr. Waxman argued Congress used the word shall to mandate data sharing.

    Mr. Waxman claimed applicants cannot disregard statutory mandates after using sponsor information.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

Sandoz seeks to delay sharing proprietary data with Amgen. Amgen demands immediate data access to start patent litigation. The Court must interpret the statutory timeline for this exchange.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on April 26, 2017.

Official sources for this section

What each side wants

Sandoz wants to delay sharing data with Amgen until the FDA approves the drug.

Amgen wants Sandoz to share data immediately to start patent litigation.

Official sources for this section

What each side says

Sandoz argues the statute allows data sharing only after FDA approval.

Amgen argues the statute mandates immediate data sharing to resolve patent disputes.

Official sources for this section

What the justices asked

Justice Sotomayor asked how long FDA approval takes after Phase II trials.

Justice Sotomayor asked when the FDA announces its intent to approve a drug.

Official sources for this section

Why it matters

This case defines the timeline for biosimilar patent litigation. It determines when generic makers must share data. It affects the speed of biosimilar market entry. It shapes the balance between patent rights and competition.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Title and summary sources

Revision history

  1. Revision 1 · Official Transcript ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Official Transcript ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON